by ddx_admin | Jun 19, 2024 | Research and Publications
DDx Founder Matt Leavitt and the DDx Foundation are proud to have assisted in executing this important research. MSI is an important biomarker for immunotherapy, but due to its low prevalence in prostate cancer, molecular testing for MSI is not standard of care....
Recent Comments